Metabolites in Safety Testing (MIST): Considerations of Mechanisms of Toxicity with Dose, Abundance, and Duration of Treatment

被引:104
作者
Smith, Dennis A. [1 ]
Obach, R. Scott [2 ]
机构
[1] Pfizer Inc, Pharmacokinet Dynam & Metab, Sandwich, Kent, England
[2] Pfizer Inc, Dynam & Metab, Groton, CT 06340 USA
关键词
HUMAN LIVER-MICROSOMES; HUMAN UDP-GLUCURONOSYLTRANSFERASES; AMMONIUM-LINKED GLUCURONIDATION; RECEPTOR ANTAGONIST CP-122,721; ALDEHYDE OXIDASE ACTIVITY; IN-VITRO; SPECIES-DIFFERENCES; N-GLUCURONIDATION; DRUG-METABOLISM; PARTIAL AGONIST;
D O I
10.1021/tx800415j
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
In previous papers, we have offered a strategic framework regarding metabolites of drugs in humans and the need to assess these in laboratory animal species (also termed Metabolites in Safety Testing or MIST; Smith and Obach, Chem. Res. Toxicol. (2006) 19, 1570-1579). Three main tenets of this framework were founded in (i) comparisons of absolute exposures (as circulating concentrations or total body burden), (ii) the nature of the toxicity mechanism (i.e., reversible interaction at specific targets versus covalent binding to multiple macromolecules), and (iii) the biological matrix in which the metabolite was observed (circulatory vs excretory). In the present review, this framework is expanded to include a fourth tenet: considerations for the duration of exposure. Basic concepts of pharmacology are utilized to rationalize the relationship between exposure (to parent drug or metabolite) and various effects ranging from desired therapeutic effects through to severe toxicities. Practical considerations of human ADME (absorption-distribution-metabolism-excretion) data, to determine which metabolites should be further evaluated for safety, are discussed. An analysis of recently published human ADME studies shows that the number of drug metabolites considered to be important for MIST can be excessively high if a simple percentage-of-parent-drug criterion is used without consideration of the aforementioned four tenets. Concern over unique human metabolites has diminished over the years as experience has shown that metabolites of drugs in humans will almost always be observed in laboratory animals, although the proportions may vary. Even if a metabolite represents a high proportion of the dose in humans and a low proportion in animals, absolute abundances in animals frequently exceed that in humans because the doses used in animal toxicology studies are much greater than therapeutic doses in humans. The review also updates the enzymatic basis for the differences between species and how these relate to MIST considerations.
引用
收藏
页码:267 / 279
页数:13
相关论文
共 96 条
[1]   Acetaminophen safety and hepatotoxicity - where do we go from here? [J].
Amar, Patrick J. ;
Schiff, Eugene R. .
EXPERT OPINION ON DRUG SAFETY, 2007, 6 (04) :341-355
[2]   In silico toxicological screening of natural products [J].
Arvidson, Kirk B. ;
Valerio, Luis G., Jr. ;
Diaz, Marilyn ;
Chanderbhan, Ronald F. .
TOXICOLOGY MECHANISMS AND METHODS, 2008, 18 (2-3) :229-242
[3]   Drug metabolites in safety testing [J].
Baillie, TA ;
Cayen, MN ;
Fouda, H ;
Gerson, RJ ;
Green, JD ;
Grossman, SJ ;
Klunk, LJ ;
LeBlanc, B ;
Perkins, DG ;
Shipley, LA .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 2002, 182 (03) :188-196
[4]  
Baldwin SJ, 1999, BRIT J CLIN PHARMACO, V48, P424
[5]   In vivo metabolism of [14C] ruboxistaurin in dogs, mice, and rats following oral administration and the structure determination of its metabolites by liquid chromatography/mass spectrometry and NMR spectroscopy [J].
Barbuch, RJ ;
Campanale, K ;
Hadden, CE ;
Zmijewski, M ;
Yi, P ;
O'Bannon, DD ;
Burkey, JL ;
Kulanthaivel, P .
DRUG METABOLISM AND DISPOSITION, 2006, 34 (02) :213-224
[6]   Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs [J].
Beconi, Maria G. ;
Reed, James R. ;
Teffera, Yohannes ;
Xia, Yuan-Qing ;
Kochansky, Christopher J. ;
Liu, David Q. ;
Xu, Shiyao ;
Elmore, Charles S. ;
Ciccotto, Suzanne ;
Hora, Donald F. ;
Stearns, Ralph A. ;
Vincent, Stella H. .
DRUG METABOLISM AND DISPOSITION, 2007, 35 (04) :525-532
[7]   SPECIES VARIATION IN HEPATIC ALDEHYDE OXIDASE ACTIVITY [J].
BEEDHAM, C ;
BRUCE, SE ;
CRITCHLEY, DJ ;
ALTAYIB, Y ;
RANCE, DJ .
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 1987, 12 (04) :307-310
[8]   SB-271258, a major metabolite in the dog of the thiazolidinedione, rosiglitazone, stimulates protein synthesis in re-differentiated rat cardiomyocytes in vitro [J].
Bell, D. ;
McDermott, B. J. .
TOXICOLOGY IN VITRO, 2006, 20 (06) :808-815
[9]   The fate of a thiazolidinedione antidiabetic agent in rat and dog [J].
Bolton, GC ;
Keogh, JP ;
East, PD ;
Hollis, FJ ;
Shore, AD .
XENOBIOTICA, 1996, 26 (06) :627-636
[10]  
Breyer-Pfaff U, 2001, DRUG METAB DISPOS, V29, P1343